T. J. Wilt, M. K. Brawer, K. M. Jones, M. J. Barry, W. J. Aronson et al., Radical prostatectomy versus observation for localized prostate cancer, N Engl J Med, vol.367, pp.203-216, 2012.

F. C. Hamdy, J. L. Donovan, J. A. Lane, M. Mason, C. Metcalfe et al., 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer, N Engl J Med, vol.375, pp.1415-1439, 2016.

T. Wiegel, D. Bartkowiak, D. Bottke, C. Bronner, U. Steiner et al., Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial, Eur Urol, vol.66, pp.243-50, 2014.

A. Berlin, J. F. Castro-mesta, L. Rodriguez-romo, D. Hernandez-barajas, J. F. Gonzalez-guerrero et al., Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis, Urol Oncol, vol.35, pp.499-506, 2017.

D. M. Berney, A. Gopalan, S. Kudahetti, G. Fisher, L. Ambroisine et al., Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study, Br J Cancer, vol.100, pp.888-93, 2009.

G. Fisher, Z. H. Yang, S. Kudahetti, H. Moller, P. Scardino et al., Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort, Br J Cancer, vol.108, pp.271-278, 2013.

J. I. Epstein, An update of the Gleason grading system, J Urol, vol.183, pp.433-473, 2010.

J. I. Epstein, M. J. Zelefsky, D. D. Sjoberg, J. B. Nelson, L. Egevad et al., A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score, Eur Urol, vol.69, pp.428-463, 2016.

M. Dowsett, T. O. Nielsen, A. 'hern, R. Bartlett, J. Coombes et al., Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group, J Natl Cancer Inst, vol.103, pp.1656-64, 2011.

M. Raap, S. Liessem, J. Ruschoff, A. Fisseler-eckhoff, A. Reiner et al., Quality assurance trials for Ki67 assessment in pathology, Virchows Arch: Int J Pathol, vol.471, pp.501-509, 2017.

A. M. Hoogland, C. F. Kweldam, and G. J. Van-leenders, Prognostic histopathological and molecular markers on prostate cancer needlebiopsies: a review, Biomed Res Int, p.341324, 2014.

J. Cuzick, G. P. Swanson, G. Fisher, A. R. Brothman, D. M. Berney et al., Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study, Lancet Oncol, vol.12, pp.245-55, 2011.

P. Stattin, J. E. Damber, L. Karlberg, and A. Bergh, Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer, J Urol, vol.157, pp.219-241, 1997.

R. Li, K. Heydon, M. E. Hammond, D. J. Grignon, M. Roach et al., Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10, Clin Cancer Res, vol.10, pp.4118-4142, 2004.

A. Pollack, M. Desilvio, L. Y. Khor, R. Li, T. I. Al-saleem et al., Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02, J Clin Oncol, vol.22, pp.2133-2173, 2004.

L. Y. Khor, K. Bae, R. Paulus, T. Al-saleem, M. E. Hammond et al., MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02, J Clin Oncol, vol.27, pp.3177-84, 2009.

M. K. Tollefson, R. J. Karnes, E. D. Kwon, C. M. Lohse, L. J. Rangel et al., Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model, Mayo Clin Proc, vol.89, pp.308-326, 2014.

M. S. Tretiakova, W. Wei, H. D. Boyer, L. F. Newcomb, S. Hawley et al., Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies, Prostate Cancer Prostatic Dis, vol.19, pp.264-70, 2016.

J. Lobo, A. Rodrigues, L. Antunes, I. Graca, J. Ramalho-carvalho et al., High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer, Urol Oncol, vol.36, pp.161-168, 2018.

W. J. Green, G. Ball, G. Hulman, C. Johnson, G. Van-schalwyk et al., KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach, Br J Cancer, vol.115, pp.236-278, 2016.

J. I. Epstein, L. Egevad, M. B. Amin, B. Delahunt, J. R. Srigley et al., Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System, International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of, vol.40, pp.244-52, 2014.

T. Tramm, M. Kyndi, F. B. Sorensen, J. Overgaard, and J. Alsner, Influence of intra-tumoral heterogeneity on the evaluation of BCL2, Ecadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer, Acta Oncol, vol.57, pp.102-108, 2018.

Z. Yang, L. H. Tang, and D. S. Klimstra, Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification, Am J Surg Pathol, vol.35, pp.853-60, 2011.

P. Leon, G. Cancel-tassin, S. Drouin, M. Audouin, J. Varinot et al., Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy, World J Urol, 2018.

A. Briganti, N. Fossati, J. Catto, P. Cornford, F. Montorsi et al., Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position, Eur Urol, vol.74, pp.357-68, 2018.

E. Richardsen, S. Andersen, S. Al-saad, M. Rakaee, Y. Nordby et al., Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort, PLoS ONE, vol.12, p.186852, 2017.